Effectiveness and tolerability of neoadjuvant pertuzumab containing regimens for HER2-positive localized breast cancer.

PURPOSE: Based on improvement in pathologic complete response (pCR) in NeoSphere and TRYPHAENA studies, the FDA approved neoadjuvant pertuzumab for HER2+ localized breast cancer. These studies demonstrated high pCR rates with THP (docetaxel+HP), FEC (5-fluorouracil, epirubicin and cyclophosphamide)-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res Treat
Auteurs principaux: Spring, Laura, Niemierko, Andrzej, Haddad, Stephanie, Yuen, Megan, Comander, Amy, Reynolds, Kerry, Shin, Jennifer, Bahn, Atul, Brachtel, Elena, Specht, Michelle, Smith, Barbara L., Taghian, Alphonse, Jimenez, Rachel, Peppercorn, Jeffrey, Isakoff, Steven J., Moy, Beverly, Bardia, Aditya
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6235701/
https://ncbi.nlm.nih.gov/pubmed/30220055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4959-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires